305 related articles for article (PubMed ID: 20855960)
61. Sorafenib and HDAC inhibitors synergize with TRAIL to kill tumor cells.
Hamed HA; Yamaguchi Y; Fisher PB; Grant S; Dent P
J Cell Physiol; 2013 Oct; 228(10):1996-2005. PubMed ID: 23674352
[TBL] [Abstract][Full Text] [Related]
62. Pyoluteorin derivatives induce Mcl-1 degradation and apoptosis in hematological cancer cells.
Doi K; Gowda K; Liu Q; Lin JM; Sung SS; Dower C; Claxton D; Loughran TP; Amin S; Wang HG
Cancer Biol Ther; 2014; 15(12):1688-99. PubMed ID: 25535900
[TBL] [Abstract][Full Text] [Related]
63. Shp2E76K mutant confers cytokine-independent survival of TF-1 myeloid cells by up-regulating Bcl-XL.
Ren Y; Chen Z; Chen L; Woods NT; Reuther GW; Cheng JQ; Wang HG; Wu J
J Biol Chem; 2007 Dec; 282(50):36463-73. PubMed ID: 17942397
[TBL] [Abstract][Full Text] [Related]
64. Expression levels of p18INK4C modify the cellular efficacy of cyclin-dependent kinase inhibitors via regulation of Mcl-1 expression in tumor cell lines.
Eguchi T; Itadani H; Shimomura T; Kawanishi N; Hirai H; Kotani H
Mol Cancer Ther; 2009 Jun; 8(6):1460-72. PubMed ID: 19509251
[TBL] [Abstract][Full Text] [Related]
65. MCL-1 Is a Key Determinant of Breast Cancer Cell Survival: Validation of MCL-1 Dependency Utilizing a Highly Selective Small Molecule Inhibitor.
Xiao Y; Nimmer P; Sheppard GS; Bruncko M; Hessler P; Lu X; Roberts-Rapp L; Pappano WN; Elmore SW; Souers AJ; Leverson JD; Phillips DC
Mol Cancer Ther; 2015 Aug; 14(8):1837-47. PubMed ID: 26013319
[TBL] [Abstract][Full Text] [Related]
66. Endogenous Bak inhibitors Mcl-1 and Bcl-xL: differential impact on TRAIL resistance in Bax-deficient carcinoma.
Gillissen B; Wendt J; Richter A; Richter A; Müer A; Overkamp T; Gebhardt N; Preissner R; Belka C; Dörken B; Daniel PT
J Cell Biol; 2010 Mar; 188(6):851-62. PubMed ID: 20308427
[TBL] [Abstract][Full Text] [Related]
67. The pan-Bcl-2 blocker obatoclax promotes the expression of Puma, Noxa, and Bim mRNA and induces apoptosis in neoplastic mast cells.
Peter B; Cerny-Reiterer S; Hadzijusufovic E; Schuch K; Stefanzl G; Eisenwort G; Gleixner KV; Hoermann G; Mayerhofer M; Kundi M; Baumgartner S; Sperr WR; Pickl WF; Willmann M; Valent P
J Leukoc Biol; 2014 Jan; 95(1):95-104. PubMed ID: 24052572
[TBL] [Abstract][Full Text] [Related]
68. Cdk1/cyclin B plays a key role in mitotic arrest-induced apoptosis by phosphorylation of Mcl-1, promoting its degradation and freeing Bak from sequestration.
Chu R; Terrano DT; Chambers TC
Biochem Pharmacol; 2012 Jan; 83(2):199-206. PubMed ID: 22024133
[TBL] [Abstract][Full Text] [Related]
69. Simultaneous exposure of transformed cells to SRC family inhibitors and CHK1 inhibitors causes cell death.
Mitchell C; Hamed HA; Cruickshanks N; Tang Y; Bareford MD; Hubbard N; Tye G; Yacoub A; Dai Y; Grant S; Dent P
Cancer Biol Ther; 2011 Aug; 12(3):215-28. PubMed ID: 21642769
[TBL] [Abstract][Full Text] [Related]
70. Proteasome inhibitors potentiate leukemic cell apoptosis induced by the cyclin-dependent kinase inhibitor flavopiridol through a SAPK/JNK- and NF-kappaB-dependent process.
Dai Y; Rahmani M; Grant S
Oncogene; 2003 Oct; 22(46):7108-22. PubMed ID: 14562039
[TBL] [Abstract][Full Text] [Related]
71. Bax/Bak activation in the absence of Bid, Bim, Puma, and p53.
Zhang J; Huang K; O'Neill KL; Pang X; Luo X
Cell Death Dis; 2016 Jun; 7(6):e2266. PubMed ID: 27310874
[TBL] [Abstract][Full Text] [Related]
72. Repression of Mcl-1 and disruption of the Mcl-1/Bak interaction in myeloma cells couple ER stress to mitochondrial apoptosis.
Gomez-Bougie P; Halliez M; Moreau P; Pellat-Deceunynck C; Amiot M
Cancer Lett; 2016 Dec; 383(2):204-211. PubMed ID: 27697610
[TBL] [Abstract][Full Text] [Related]
73. Distinct cellular and therapeutic effects of obatoclax in rituximab-sensitive and -resistant lymphomas.
Brem EA; Thudium K; Khubchandani S; Tsai PC; Olejniczak SH; Bhat S; Riaz W; Gu J; Iqbal A; Campagna R; Knight J; Mavis C; Hoskin P; Deeb G; Gibbs JF; Fetterly G; Czuczman MS; Hernandez-Ilizaliturri FJ
Br J Haematol; 2011 Jun; 153(5):599-611. PubMed ID: 21492126
[TBL] [Abstract][Full Text] [Related]
74. DMFC (3,5-dimethyl-
Xiang J; Wang Z; Liu Q; Li X; Sun J; Fung KP; Liu F
Apoptosis; 2017 Mar; 22(3):381-392. PubMed ID: 27873035
[TBL] [Abstract][Full Text] [Related]
75. Sorafenib sensitizes (-)-gossypol-induced growth suppression in androgen-independent prostate cancer cells via Mcl-1 inhibition and Bak activation.
Lian J; Ni Z; Dai X; Su C; Smith AR; Xu L; He F
Mol Cancer Ther; 2012 Feb; 11(2):416-26. PubMed ID: 22188816
[TBL] [Abstract][Full Text] [Related]
76. Vaccinia virus F1L interacts with Bak using highly divergent Bcl-2 homology domains and replaces the function of Mcl-1.
Campbell S; Hazes B; Kvansakul M; Colman P; Barry M
J Biol Chem; 2010 Feb; 285(7):4695-708. PubMed ID: 19955184
[TBL] [Abstract][Full Text] [Related]
77. Roscovitine sensitizes breast cancer cells to TRAIL-induced apoptosis through a pleiotropic mechanism.
Ortiz-Ferrón G; Yerbes R; Eramo A; López-Pérez AI; De Maria R; López-Rivas A
Cell Res; 2008 Jun; 18(6):664-76. PubMed ID: 18458681
[TBL] [Abstract][Full Text] [Related]
78. Key Survival Factor, Mcl-1, Correlates with Sensitivity to Combined Bcl-2/Bcl-xL Blockade.
Williams MM; Lee L; Hicks DJ; Joly MM; Elion D; Rahman B; McKernan C; Sanchez V; Balko JM; Stricker T; Estrada MV; Cook RS
Mol Cancer Res; 2017 Mar; 15(3):259-268. PubMed ID: 28039357
[TBL] [Abstract][Full Text] [Related]
79. Vesicular stomatitis virus induces apoptosis primarily through Bak rather than Bax by inactivating Mcl-1 and Bcl-XL.
Pearce AF; Lyles DS
J Virol; 2009 Sep; 83(18):9102-12. PubMed ID: 19587033
[TBL] [Abstract][Full Text] [Related]
80. Flavopiridol and histone deacetylase inhibitors promote mitochondrial injury and cell death in human leukemia cells that overexpress Bcl-2.
Dasmahapatra G; Almenara JA; Grant S
Mol Pharmacol; 2006 Jan; 69(1):288-98. PubMed ID: 16219908
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
